FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3097856296> ?p ?o ?g. }

• W3097856296 endingPage "932" @default.
• W3097856296 startingPage "920" @default.
• W3097856296 abstract "Multiple combination therapies with chemotherapeutic drugs and inhibitors of drug resistance have been effective in the clinical cases, but concerns have been raised about the severe toxicity of these chemotherapeutic drugs. Herein, we report a potent and safe combination strategy of cancer-specific doxorubicin (DOX) prodrug nanoparticles (PNPs) and B-cell lymphoma-2 (Bcl-2) anti-apoptotic inhibitor, Navitoclax, to overcome acquired drug resistance during chemotherapy. The cancer-specific PNPs were constructed by conjugating cathepsin B-specific cleavable peptide (Phe-Arg-Arg-Gly; FRRG) to DOX, resulting in FRRG-DOX that self-assembled into nanoparticles and the FRRG-DOX nanoparticles were further stabilized with the FDA-approved pharmaceutical excipient, Pluronic F68. The resulting PNPs are specifically cleaved and metabolized to free DOX in cathepsin B-overexpressing cancer cells, but they exhibited minimal cytotoxicity in cathepsin B-deficient normal cells. As expected, free DOX and PNPs induced overexpression of Bcl-2 in MDA-MB-231 cells, due to acquired drug resistance in a cell culture system. However, combination therapy with PNPs and Navitoclax showed the outstanding synergetic cytotoxicity by decreasing the expression level of Bcl-2. In MDA-MB231 breast tumor-bearing mice, intravenously injected PNPs efficiently accumulated in targeted tumor tissues via enhanced permeability and retention (EPR) effect. When combined with orally administered Navitoclax, PNPs exhibited more potent therapeutic efficacy in aquired drug resistant models than free DOX plus Navitoclax, whereas PNPs greatly reduced systemic toxic side effects in normal organs. Our cancer-specific PNP-based combination therapy with Bcl-2 inhibitor may provide a promising approach for the potent and safe treatment of acquired drug-resistant cancers." @default.
• W3097856296 created "2020-11-09" @default.
• W3097856296 creator A5004353244 @default.
• W3097856296 creator A5028371225 @default.
• W3097856296 creator A5029505798 @default.
• W3097856296 creator A5030603383 @default.
• W3097856296 creator A5043658693 @default.
• W3097856296 creator A5055447223 @default.
• W3097856296 creator A5065286478 @default.
• W3097856296 creator A5088717584 @default.
• W3097856296 date "2021-02-01" @default.
• W3097856296 modified "2023-10-16" @default.
• W3097856296 title "Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance" @default.
• W3097856296 cites W1966226982 @default.
• W3097856296 cites W1969604041 @default.
• W3097856296 cites W1971310926 @default.
• W3097856296 cites W1974523261 @default.
• W3097856296 cites W1980832510 @default.
• W3097856296 cites W1992172691 @default.
• W3097856296 cites W2018614615 @default.
• W3097856296 cites W2029071448 @default.
• W3097856296 cites W2042619042 @default.
• W3097856296 cites W2064674946 @default.
• W3097856296 cites W2067275727 @default.
• W3097856296 cites W2073131323 @default.
• W3097856296 cites W2095124748 @default.
• W3097856296 cites W2095142763 @default.
• W3097856296 cites W2100545793 @default.
• W3097856296 cites W2103450589 @default.
• W3097856296 cites W2105218405 @default.
• W3097856296 cites W2109124443 @default.
• W3097856296 cites W2113278680 @default.
• W3097856296 cites W2115268409 @default.
• W3097856296 cites W2120703739 @default.
• W3097856296 cites W2131487381 @default.
• W3097856296 cites W2147328441 @default.
• W3097856296 cites W2536814636 @default.
• W3097856296 cites W2554168993 @default.
• W3097856296 cites W2567338548 @default.
• W3097856296 cites W2904107490 @default.
• W3097856296 cites W2905402249 @default.
• W3097856296 cites W2980964730 @default.
• W3097856296 doi "https://doi.org/10.1016/j.jconrel.2020.10.065" @default.
• W3097856296 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33152391" @default.
• W3097856296 hasPublicationYear "2021" @default.
• W3097856296 type Work @default.
• W3097856296 sameAs 3097856296 @default.
• W3097856296 citedByCount "36" @default.
• W3097856296 countsByYear W30978562962021 @default.
• W3097856296 countsByYear W30978562962022 @default.
• W3097856296 countsByYear W30978562962023 @default.
• W3097856296 crossrefType "journal-article" @default.
• W3097856296 hasAuthorship W3097856296A5004353244 @default.
• W3097856296 hasAuthorship W3097856296A5028371225 @default.
• W3097856296 hasAuthorship W3097856296A5029505798 @default.
• W3097856296 hasAuthorship W3097856296A5030603383 @default.
• W3097856296 hasAuthorship W3097856296A5043658693 @default.
• W3097856296 hasAuthorship W3097856296A5055447223 @default.
• W3097856296 hasAuthorship W3097856296A5065286478 @default.
• W3097856296 hasAuthorship W3097856296A5088717584 @default.
• W3097856296 hasConcept C108215921 @default.
• W3097856296 hasConcept C109316439 @default.
• W3097856296 hasConcept C121608353 @default.
• W3097856296 hasConcept C126322002 @default.
• W3097856296 hasConcept C181199279 @default.
• W3097856296 hasConcept C185592680 @default.
• W3097856296 hasConcept C202751555 @default.
• W3097856296 hasConcept C2776694085 @default.
• W3097856296 hasConcept C2781303535 @default.
• W3097856296 hasConcept C28021979 @default.
• W3097856296 hasConcept C502942594 @default.
• W3097856296 hasConcept C55493867 @default.
• W3097856296 hasConcept C71924100 @default.
• W3097856296 hasConcept C96232424 @default.
• W3097856296 hasConcept C98274493 @default.
• W3097856296 hasConceptScore W3097856296C108215921 @default.
• W3097856296 hasConceptScore W3097856296C109316439 @default.
• W3097856296 hasConceptScore W3097856296C121608353 @default.
• W3097856296 hasConceptScore W3097856296C126322002 @default.
• W3097856296 hasConceptScore W3097856296C181199279 @default.
• W3097856296 hasConceptScore W3097856296C185592680 @default.
• W3097856296 hasConceptScore W3097856296C202751555 @default.
• W3097856296 hasConceptScore W3097856296C2776694085 @default.
• W3097856296 hasConceptScore W3097856296C2781303535 @default.
• W3097856296 hasConceptScore W3097856296C28021979 @default.
• W3097856296 hasConceptScore W3097856296C502942594 @default.
• W3097856296 hasConceptScore W3097856296C55493867 @default.
• W3097856296 hasConceptScore W3097856296C71924100 @default.
• W3097856296 hasConceptScore W3097856296C96232424 @default.
• W3097856296 hasConceptScore W3097856296C98274493 @default.
• W3097856296 hasFunder F4320321373 @default.
• W3097856296 hasFunder F4320322091 @default.
• W3097856296 hasFunder F4320322120 @default.
• W3097856296 hasLocation W30978562961 @default.
• W3097856296 hasOpenAccess W3097856296 @default.
• W3097856296 hasPrimaryLocation W30978562961 @default.
• W3097856296 hasRelatedWork W1587028183 @default.
• W3097856296 hasRelatedWork W2007511662 @default.

• next